The grades of seven pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc. (PATH) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR (GWPH) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
The rating of Lipocine, Inc. (LPCN) moves up this week, rising from a C to a B. Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.
Cardiome Pharma’s (CRME) ratings are looking better this week, moving up to a B from last week’s C. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc. (ABBV) boosts its rating from a C to a B this week. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Dipexium Pharmaceuticals, Inc. (DPRX) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of DPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
